Lhasa Limited

shared knowledge shared progress

ABOUT US |
CONTACT US |
CAREERS |
Login

Related News

Lhasa Limited releases new data to it's Nitrites in Excipients project users
Lhasa Limited is pleased to release new data to it's Nitrites in Excipients project users.
04 June 2021
Lhasa Limited releases new data into its Intermediates Database
25 May 2021
Lhasa Limited releases new data to its AI/PDE project users
26 April 2021

Related Blog Articles

The top 5 benefits of data sharing with Vitic [an infographic]
Lhasa Limited has been an advocate of data sharing for many years. In this piece, we explore the top 5 benefits of data sharing with Vitic.
08 April 2021
Working together to address the potential presence of nitrosamine impurities in medications
25 January 2021
Lhasa Limited supports the global challenge of nitrosamine impurity assessment
13 July 2020

Recent News

Lhasa Limited releases Nexus 2.4 with enhanced ICH M7 expert review support
To enhance expert review assessment support, Nexus 2.4 includes a new flag to alert the reviewer when a compound is in the ICH M7 “cohort of concern”.
22 July 2021

Recent Blog Articles

Accessing vital sources of long-term carcinogenicity study data with Lhasa’s Carcinogenicity Database
In this blog piece, we explore in more detail, the features of the recent release and how they will benefit LCDB users.
12 July 2021

Recent Publications

Upcoming Events

Virtual Conference: 2021 (11th) World Congress on Alternatives and Animal Use in the Life Sciences
Aug 23 2021
Virtual Conference: EUROTOX 2021
Sep 27 2021
Conference: 2021 ACT - 42nd Annual Meeting
Nov 14 2021

Recent News

Lhasa Limited releases Nexus 2.4 with enhanced ICH M7 expert review support
To enhance expert review assessment support, Nexus 2.4 includes a new flag to alert the reviewer when a compound is in the ICH M7 “cohort of concern”.
22 July 2021
Lhasa Limited releases new data to it's Nitrites in Excipients project users
04 June 2021
Lhasa Limited releases new data into its Intermediates Database
25 May 2021

Recent Blog Articles

Accessing vital sources of long-term carcinogenicity study data with Lhasa’s Carcinogenicity Database
In this blog piece, we explore in more detail, the features of the recent release and how they will benefit LCDB users.
12 July 2021
10 tips for controlling your potentially mutagenic impurities outside the lab
30 June 2021
A day in the life of a Scientist at Lhasa Limited
28 May 2021

Archive

This is a library of Lhasa's blog articles.

5 minutes
Effiris: A secondary pharmacology model suite powered by privacy-preserving data sharing
Artificial Intelligence (AI) has become a powerful force within the pharmaceutical industry, catalysed by the challenging lengthy and costly drug development process. To maximize the impact of AI, it is critical to have access to enough good quality data to allow machine learning algorithms to extract relevant knowledge and produce valuable models.
- Innovation
21 May 2020
less than 5 minutes
How to better anticipate and mitigate adverse drug reactions [an infographic]
Are you interested in using your data to anticipate and mitigate adverse drug reactions? The Effiris consortium - currently composed of Takeda, GSK and UCB - is working to achieve just that.
- Innovation
17 February 2021

Sitemap

© 2021 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020
VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wales).

Apart from the free survey software, we also have access to QuestionPro's free survey templates . We've found many of them useful and powerful to collect insights from various stakeholders of our organization.